autologous tumor cell-TLR9 agonist vaccine (University of Stanford)

N/A

Report date: 2026/01/22 16:42:21

Base Information

Drug Nameautologous tumor cell-TLR9 agonist vaccine (University of Stanford)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine
Mechanisms of ActionToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesStanford University
Active IndicationsN/A
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A